← 返回

错配修复缺陷及对肿瘤的淋巴细胞反应作为 II 期结肠癌患者的预后标志物

英文原题:Deficient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients.

查看英文原题

Deficient Mismatch Repair and Lymphocytic Response to Tumor as Prognostic Markers in Stage II Colon Cancer Patients.

PubMed 2022/02/01(内容时间) J Coll Physicians Surg Pak Q3 · IF 1.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TIL 与 MMR 的联合应用可能使我们能够更详细地区分患者的生存结局。因此,考虑到通过 IHC 评估的 TIL 和 MMR 状态可能是 II 期结肠癌患者风险分层的一种具有成本效益且有效的选择。关键词:淋巴细胞反应,错配修复,预后,TIL(肿瘤浸润淋巴细胞),II 期癌症,结肠癌。

研究思路结论见上方概要

探讨由TIL(肿瘤浸润淋巴细胞)状态和错配修复(MMR)联合定义的结肠癌(CC)亚型与临床病理特征及生存之间的关系。

观察性研究。研究地点和时间:土耳其伊斯坦布尔Haydarpaşa Numune研究与培训医院肿瘤内科,2010年7月至2020年3月。研究纳入83例接受手术的II期结肠癌患者。从患者档案中获取病理、手术、肿瘤治疗及随访信息;并对总生存期(OS)进行统计分析。通过免疫组织化学方法确定TIL(肿瘤浸润淋巴细胞)和错配修复状态。

分别有26例(31.3%)和21例(25.3%)患者检测到TIL-high和dMMR状态。根据TIL和MMR状态将肿瘤分为四个亚组。TIL-high/dMMR肿瘤预后最佳,而TIL-low/pMMR肿瘤OS较差。

展开英文摘要原文

To investigate the relationship between colon cancer (CC) subtypes defined by the status of tumor-infiltrating lymphocytes (TIL) and mismatch repair (MMR) combination with clinicopathological features and survival. STUDY DESIGN: Observational study. PLACE AND DURATION OF STUDY: Department of Medical Oncology, Haydarpa a Numune Research and Training Hospital, Istanbul, Turkey, from July 2010 to March 2020. METHODOLOGY: Eighty-three patients with operated stage II colon cancer were included in the study. Pathology, surgery and oncological treatment and follow-up information were obtained from patient files; and statistical analyses were performed on overall survival (OS). Tumor-infiltrating lymphocytes and mismatch repair status was determined with the help of immunohistochemistry.

TIL-high and deficient MMR (dMMR) status were detected in 26 patients (31.3%) and 21 patients (25.3%), respectively. Tumors were divided into four subgroups according to TIL and MMR status. TIL-high/dMMR tumors had the most favourable prognosis, while TIL-low/proficient MMR tumors exhibited poor OS.

The combination of TIL and MMR could enable us to differentiate patients' survival outcomes in more details. Therefore, considering that the TIL and MMR status, evaluated by IHC, may be a cost-effective and effective option for risk classification in patients with stage II colon cancer. Key Word: Lymphocytic response, Mismatch repair, Prognosis, Tumor-infiltrating lymphocytes, Stage II cancer, Colon cancer.

论文信息

作者
Sari M、Atag E、Demir T、Simsek ET、Coban E、Cikrikcioglu M
第一作者单位
Department of Medical Oncology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey.Turkey
通讯作者单位
Department of Pathology, Haydarpasa Numune Research and Training Hospital, Istanbul, Turkey.Turkey
文献类型
观察性研究
期刊
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP2022 Feb
原文标识
PubMed 35108789 · DOI 10.29271/jcpsp.2022.02.186